within Pharmacolibrary.Drugs.S_SensoryOrgans.S01G_DecongestantsAndAntiallergics.S01GX02_Levocabastine;
model Levocabastine 
   extends Pharmacolibrary.Drugs.ATC.S.S01GX02;

  annotation(Documentation(
    info ="<html><body><p>Levocabastine is a selective second-generation histamine H1 receptor antagonist used primarily as an ophthalmic solution for symptomatic relief of allergic conjunctivitis. It is administered topically and has minimal systemic effects due to low absorption. Levocabastine is approved in some countries for ocular and intranasal use for allergic symptoms.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers after ocular administration.</p><h4>References</h4><ol><li><p>Heykants, J, et al., &amp; Woestenborghs, R (1995). The pharmacokinetic properties of topical levocabastine. A review. <i>Clinical pharmacokinetics</i> 29(4) 221–230. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199529040-00002&quot;>10.2165/00003088-199529040-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8549024/&quot;>https://pubmed.ncbi.nlm.nih.gov/8549024</a></p></li><li><p>Dechant, KL, &amp; Goa, KL (1991). Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. <i>Drugs</i> 41(2) 202–224. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199141020-00006&quot;>10.2165/00003495-199141020-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1709851/&quot;>https://pubmed.ncbi.nlm.nih.gov/1709851</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Levocabastine;
